Anticancer carbonic anhydrase inhibitors: a patent review (2008 – 2013)

Bibliography

• Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421-68
   PubMed Web of Science ®Google Scholar
• Supuran C. Carbonic anhydrases: catalytic and inhibition mechanisms, distribution and physiological roles. In: Supuran CT, Scozzafava A, Conway J, editors. Carbonic anhydrase: its inhibitors and activators. CRC Press, Boca Raton, FL; 2004. p. 1-23
   Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-81
   PubMed Web of Science ®Google Scholar
• Guler OO, De Simone G, Supuran CT. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr Med Chem 2010;17:1516-26
   PubMed Web of Science ®Google Scholar
• Pastoreková S, Pastorek J. Cancer-related carbonic anhydrase isoenzymes and their inhibition. In: Supuran CT, Scozzafava A, Conway J, editors. Carbonic anhydrase: its inhibitors and activators. CRC Press, Boca Raton, FL; 2004. p. 255-81
   Google Scholar
• Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905-19
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 2008;14:685-98
   PubMed Web of Science ®Google Scholar
• Supuran CT, Di Fiore A, Alterio V, et al. Recent advances in structural studies of the carbonic anhydrase family: the crystal structure of human CA IX and CA XIII. Curr Pharm Des 2010;16:3246-54
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. Carbonic anhydrase IX: biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta 2010;1804:404-9
   PubMed Web of Science ®Google Scholar
• Stillebroer AB, Mulders PF, Boerman OC, et al. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010;58:75-83
   PubMed Web of Science ®Google Scholar
• Monti SM, Supuran CT, De Simone G. Carbonic anhydrase IX as a target for designing novel anticancer drugs. Curr Med Chem 2012;19:821-30
   PubMed Web of Science ®Google Scholar
• Opavský R, Pastoreková S, Zelník V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996;33:480-7
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastoreková S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994;9:2877-88
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-83
   PubMed Web of Science ®Google Scholar
• Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004;3:164-7
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Barathova M, Kopacek J, Pastorek J. Carbonic anhydrase inhibitors targeting cancer: therapeutic, immunologic, and diagnostic tools targeting isoforms IX and XII. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken. Wiley, New Jersey; 2009. p. 193-222
   Google Scholar
• Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007;26:299-310
   PubMed Web of Science ®Google Scholar
• Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumor acidity and implications for treatment. Mol Med Today 2000;6:15-19
   PubMedGoogle Scholar
• Helmlinger G, Sckell A, Dellian M, et al. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2002;8:1284-91
   PubMed Web of Science ®Google Scholar
• Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007;101:937-49
   PubMed Web of Science ®Google Scholar
• Lee AH, Tannock IF. Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res 1998;58:1901-8
   PubMed Web of Science ®Google Scholar
• Chiche J, Brahimi-Horn MC, Pouysségur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 2010;14:771-94
   PubMed Web of Science ®Google Scholar
• Brahimi-Horn MC, Pouysségur J. Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem 2007;43:165-78
   PubMed Web of Science ®Google Scholar
• Svastova E, Zilka N, Zat'ovicova M, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res 2003;290:332-45
   PubMed Web of Science ®Google Scholar
• Zavadova Z, Zavada J. Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment. Oncol Rep 2005;13:977-82
   PubMed Web of Science ®Google Scholar
• Zavada J, Zavadova Z, Pastorek J, et al. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000;82:1808-13
   PubMed Web of Science ®Google Scholar
• Innocenti A, Pastorekova S, Pastorek J, et al. The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as an intrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors. Bioorg Med Chem Lett 2009;19:5825-8
   PubMed Web of Science ®Google Scholar
• Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA 2009;106:16233-8
   PubMed Web of Science ®Google Scholar
• Ditte P, Dequiedt F, Svastova E, et al. Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res 2011;71:7558-67
   PubMed Web of Science ®Google Scholar
• Dorai T, Sawczuk IS, Pastorek J, et al. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005;41:2935-47
   PubMed Web of Science ®Google Scholar
• Hulikova A, Zatovicova M, Svastova E, et al. Intact intracellular tail is critical for proper functioning of the tumor-associated, hypoxia-regulated carbonic anhydrase IX. FEBS Lett 2009;583:3563-8
   PubMed Web of Science ®Google Scholar
• Buanne P, Renzone G, Monteleone F, et al. Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells. J Proteome Res 2013;12:282-92
   PubMed Web of Science ®Google Scholar
• Hilvo M, Baranauskiene L, Salzano AM, et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008;283:27799-809
   PubMed Web of Science ®Google Scholar
• Türeci O, Sahin U, Vollmar E, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA 1998;95:7608-13
   PubMed Web of Science ®Google Scholar
• Ivanov SV, Kuzmin I, Wei MH, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998;95:12596-601
   PubMed Web of Science ®Google Scholar
• Hynninen P, Vaskivuo L, Saarnio J, et al. Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 2006;49:594-602
   PubMed Web of Science ®Google Scholar
• Kim JY, Shin HJ, Kim TH, et al. Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J Cancer Res Clin Oncol 2006;132:302-8
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Laferrière J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009;69:358-68
   PubMed Web of Science ®Google Scholar
• Haapasalo J, Hilvo M, Nordfors K, et al. Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. Neuro Oncol 2008;10:131-8
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley N, Watson PH, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 2001;158:1011-19
   PubMed Web of Science ®Google Scholar
• Hsieh MJ, Chen KS, Chiou HL, Hsieh YS. Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway. Eur J Cell Biol 2010;89:598-606
   PubMed Web of Science ®Google Scholar
• Kivela AJ, Parkkila S, Saarnio J, et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol 2000;114:197-204
   PubMed Web of Science ®Google Scholar
• Kivela A, Parkkila S, Saarnio J, et al. Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am J Pathol 2000;156:577-84
   PubMed Web of Science ®Google Scholar
• Kivela AJ, Parkkila S, Saarnio J, et al. Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa. World J Gastroenterol 2005;11:2616-25
   PubMed Web of Science ®Google Scholar
• Ilie MI, Hofman V, Ortholan C, et al. Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. Int J Cancer 2011;128:1614-23
   PubMed Web of Science ®Google Scholar
• Karhumaa P, Parkkila S, Türeci O, et al. Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium. Mol Hum Reprod 2000;6:68-74
   PubMed Web of Science ®Google Scholar
• Parkkila S, Parkkila AK, Saarnio J, et al. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. J Histochem Cytochem 2000;48:1601-8
   PubMed Web of Science ®Google Scholar
• Liao SY, Ivanov S, Ivanova A, et al. Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma. J Med Genet 2003;40:257-61
   PubMed Web of Science ®Google Scholar
• Hussain SA, Ganesan R, Reynolds G, et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 2007;96:104-9
   PubMed Web of Science ®Google Scholar
• Whittington DA, Waheed A, Ulmasov B, et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA 2001;98:9545-50
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases as drug targets. Curr Pharm Des 2008;14:601-2
   PubMed Web of Science ®Google Scholar
• Svastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577:439-45
   PubMed Web of Science ®Google Scholar
• Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005;48:4834-41
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Mastrolorenzo A, Supuran CT. Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin Ther Pat 2004;14:667-702
   Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467-74
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-89
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Casini A, Scozzafava A, et al. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:869-73
   PubMed Web of Science ®Google Scholar
• Thiry A, Dogné J-M, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006;27:566-73
   PubMed Web of Science ®Google Scholar
• Carta F, Scozzafava A, Supuran CT. Sulfonamides: a patent review (2008 - 2012). Expert Opin Ther Pat 2012;22:747-58
   PubMed Web of Science ®Google Scholar
• Nicox SA, Supuran CT, Benedini F, et al. Nitrate esters of carbonic anhydrase inhibitors. WO071421; 2008
   Google Scholar
• Stichting Maastricht Radiation Oncology Maastro Clinic. Dubois LJ, Lambin P, et al. Cancer targeting using carbonic anhydrase isoform IX inhibitors. WO087115; 2012
   Google Scholar
• Molecular Insight Pharm, Inc. Zimmerman C, Babich JW, et al. Inhibitors of carbonic anhydrase IX. WO089383; 2009
   Google Scholar
• Univ Firenze, Uni Oslo, Univ Manchester. et al. Carbonic anhydrase inhibitors. WO098610; 2011
   Google Scholar
• Univ Notre Dame de la Paix. Masereel B, Frederick R, Supuran CT. Tetraline sulfonamide derivatives for use in the treatment of proliferative disorders. WO175654; 2012
   Google Scholar
• Auspex Pharmaceuticals, Inc. Sulfonamide inhibitors of Carbonic anhydrase. US2010317655; 2010
   Google Scholar
• Casey JR, Morgan PE, Vullo D, et al. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem 2004;47:2337-47
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Briganti F, Ilies MA, Supuran CT. Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J Med Chem 2000;43:292-300
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Ilies MA, Briganti F. Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes. J Enzyme Inhib 2000;15:381-401
   PubMed Web of Science ®Google Scholar
• Institute of Virology of the Slovak Academy of Sciences. CA IX-specific inhibitors. US095707; 2008
   Google Scholar
• Scozzafava A; Institute of Virology, Supuran CT. CA IX-specific inhibitors. AU211499; 2012
   Google Scholar
• Institute of Virology. Supuran C, Scozzafava A. CA IX-specific inhibitors. AU200368; 2010
   Google Scholar
• Institute of Virology of the Slovak Academy of Sciences. CA IX-specific inhibitors. US220001; 2008
   Google Scholar
• Dubois L, Douma K, Supuran CT, et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 2007;83:367-73
   PubMed Web of Science ®Google Scholar
• Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol 2009;92:423-8
   PubMed Web of Science ®Google Scholar
• Union Life Sciences Ltd. Sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents. US138291; 2008
   Google Scholar
• Supuran CT, Scozzafava A. Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents. WO 137092; 2006
   Google Scholar
• Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb) 2010;46:8371-3
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896-902
   PubMed Web of Science ®Google Scholar
• MetaSignal Therapeutics, Inc. Supuran C, Dedhar S, et al. Novel sulfonamide compounds for inhibition of metastatic tumor growth. WO021963; 2012
   Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057-62
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Pochet L, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010;53:335-44
   PubMed Web of Science ®Google Scholar
• Maresca A, Scozzafava A, Supuran CT. 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg Med Chem Lett 2010;20:7255-8
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364-76
   PubMed Web of Science ®Google Scholar
• MetaSignal Therapeutics, Inc. Supuran C, Dedhar S, et al. Carbonic anhydrase inhibitors with antimetastatic activity. WO070024; 2012
   Google Scholar
• Supuran CT, Scozzafava A, Ilies MA, et al. Carbonic anhydrase inhibitors — Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: the first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV. Eur J Med Chem 1998;33:577-94
   Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 2012; doi: 10.1038/onc.2012.550
   Google Scholar
• Vu H, Pham NB, Quinn RJ. Direct screening of natural product extracts using mass spectrometry. J Biomol Screen 2008;13:265-75
   PubMed Web of Science ®Google Scholar
• Maresca A, Supuran CT. Coumarins incorporating hydroxy- and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. Bioorg Med Chem Lett 2010;20:4511-14
   PubMed Web of Science ®Google Scholar
• Univ Tampere. Supuran CT, Parkkila S. Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms. WO139678; 2010
   Google Scholar
• Parkkila S, Innocenti A, Kallio H, et al. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. Bioorg Med Chem Lett 2009;19:4102-6
   PubMed Web of Science ®Google Scholar
• Univ Brown. Composition and methods for loop diuretics with consistent bioavailability. US0053156; 2012
   Google Scholar
• Feldman DL, Webb RL. Pharmaceutical composition comprising a renin inhibitor, calcium channel blocker and a diuretic. US0071470; 2012
   Google Scholar
• Neurotherapeutics Pharma, Inc. Diuretic and diuretic-like compound analogs. US234721; 2012
   Google Scholar
• Sanofi Aventis. Combination of dronedarone with at least one diuretic, and therapeutic use thereof. US0136899; 2011
   Google Scholar
• Woo SH. Controlling body fluid condition using diuretics. WO029899; 2009
   Google Scholar
• Bayer Schering Pharma Ag. Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin-II antagonist and/or a diuretic. MX005023; 2011
   Google Scholar
• Sciele Pharma, Inc. Dillaha L, Schutter E. Alpha-2-Adrenergic agonists and angiotensin II receptor antagonist composition. WO065489; 2010
   Google Scholar
• Pharmascience, Inc. Talwar N, Sebastian D, Philip M. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide. WO147026; 2011
   Google Scholar
• Supuran CT. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des 2008;14:641-8
   PubMed Web of Science ®Google Scholar
• Lee HS, Bae T, Lee JH, et al. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst Biol 2012;6-80
   PubMedGoogle Scholar
• Pastorekova S, Parkkila S, Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 2006;42:167-216
   PubMed Web of Science ®Google Scholar
• Battke C, Kremmer E, Mysliwietz J, et al. Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol Immunother 2011;60:649-58
   PubMed Web of Science ®Google Scholar